Shots:
- The CHMP has recommended Pebrilzo, a biosimilar version of Perjeta (pertuzumab), as the 420 mg concentrate solution for infusion for the treatment of HER2+ breast cancer across multiple disease stages
- The EC will conduct the final review and issue its decision; if positive, the SmPC will be available in all EU official languages, with the EPAR published on the EMA website in the following wks.
- Pebrilzo is a monoclonal antibody that binds with high affinity and specificity to HER2, inhibiting the proliferation of tumor cells that overexpress HER2
Ref: Biocon Biologics | Image: Biocon Biologics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
